Search alternatives:
significant based » significant cause (Expand Search), significant barrier (Expand Search), significant burden (Expand Search)
based decrease » caused decreased (Expand Search), marked decrease (Expand Search), based defense (Expand Search)
shape decrease » shape increases (Expand Search), step decrease (Expand Search), showed decreased (Expand Search)
small decrease » small increased (Expand Search)
significant based » significant cause (Expand Search), significant barrier (Expand Search), significant burden (Expand Search)
based decrease » caused decreased (Expand Search), marked decrease (Expand Search), based defense (Expand Search)
shape decrease » shape increases (Expand Search), step decrease (Expand Search), showed decreased (Expand Search)
small decrease » small increased (Expand Search)
-
2021
Presentation 1_Efficacy of disitamab vedotin in non-small cell lung cancer with HER2 alterations: a multicenter, retrospective real-world study.pdf
Published 2024“…Background<p>Non-small cell lung cancer (NSCLC) with human epidermal growth factor receptor 2 (HER2) alterations poses a substantial treatment challenge. …”
-
2022
Expression of <i>EBI2, CH25H, CYP7B1</i> and <i>HSD3B7</i> enzymes in human brain vascular cells.
Published 2025Subjects: -
2023
-
2024
-
2025
LPS induces changes in the expression of Ebi2, Ch25h, Cyp7b1 and Hsd3b7 enzymes in the mouse brain.
Published 2025Subjects: -
2026
-
2027
Tight junction and adhesion proteins in the brain are downregulated during systemic inflammation.
Published 2025Subjects: -
2028
-
2029
-
2030
-
2031
Data Sheet 1_Induction immunochemotherapy followed by definitive chemoradiotherapy and consolidation immunotherapy for unresectable stage III non-small cell lung cancer: a multi-in...
Published 2025“…Background<p>For unresectable stage III non-small cell lung cancer (NSCLC), the standard regimen is definitive concurrent chemoradiotherapy (CRT) followed by consolidation immunotherapy. …”
-
2032
-
2033
-
2034
-
2035
-
2036
-
2037
-
2038
-
2039
-
2040